Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

Aryl C-glycosides as selectin inhibitors jointly developed by Sankyo, Glycomed

Nov. 5, 1998

Potent and selective COX-2 inhibitors from Merck Frosst useful for inflammation

Nov. 4, 1998

Korean laboratory prepares new series of TNF-alpha inhibitors

Nov. 4, 1998

FDA approves, Immunex launches breakthrough treatment for RA

Nov. 3, 1998

Orally active collagenase inhibitor Ro-32-3555 shows potential for osteoarthritis Rx

Nov. 3, 1998

Preparation and use of TNF-alpha and MMP inhibitors described by Novartis

Nov. 3, 1998

Safety and efficacy of COX-2 inhibitor established in phase II trials

Nov. 2, 1998

Prosorba Column recommended for approval by FDA advisory panel

Nov. 2, 1998

Vertex and HMR initiate phase I clinical trial with HMR-3480/VX-740

Oct. 30, 1998

New COX-2 inhibitor scheduled for FDA advisory committee review in early December

Oct. 30, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...